Yourgene

Yourgene will provide molecular COVID-19 testing to corporate clients of Caxton, who will obtain their results through Hooha Innovations' Prova app.

The test has been developed to run on Illumina's NextSeq 550Dx next-generation sequencing platform and will be prepared for commercial launch in Europe.

News items for the in vitro diagnostics industry for the week of May 25, 2020.

Revenues for the fiscal year totaled £16.6 million ($20.7 million), up from £8.9 million during FY 2018.

Yourgene will use its manufacturing facility at Citylabs in Manchester to ramp up production of the test, which was developed by Novacyt's Primerdesign division.

AdGeniX started distributing Yourgene's Iona test in France in 2015 and has rapidly grown sales for the test, a trend that is expected to continue.

The genotyping test is designed to identify cancer patients with a metabolic disorder that can result in toxicity to a common cancer therapeutic.

Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.

The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.